Intrabeam TARGIT IORT is targeted intraoperative radiotherapy treatment for breast cancer. Conceived in the UK more than 20 years ago, thoroughly tested in clinical trials, TARGIT IORT treatment is widely used to treat breast cancer patients across the world.
“The most important benefit of TARGIT for a woman with breast cancer is that it allows her to complete her entire local treatment [lumpectomy and radiation therapy] at the time of her operation, with lower toxicity.” Lancet 2014;383:603-613
Using TARGIT-IORT during lumpectomy for breast cancer patients could be of special relevance during the current COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2. This is because by taking TARGIT-IORT during lumpectomy, subsequent travel for postoperative radiotherapy could be entirely avoided. Viral exposure of this vulnerable population would be greatly reduced. Many centres are already increasing the availability of this treatment and TARGIT-IORT for breast cancer has been recommended in national and international guidelines -
A Patient's View
National TV: NICE Recommendation
Environmental and Social Benefits
The TARGIT-A randomised clinical trial of Intrabeam TARGIT IORT
About 70% of patients with breast cancer are eligible for breast-conserving surgery (a lumpectomy), after which the remaining breast is treated with radiotherapy; this avoids a full mastectomy. Traditionally, external beam radiotherapy (EBRT) is delivered to the entire breast in small doses every day for 3– 6 weeks, necessitating patients to travel to and from the radiotherapy centre every working day. This can be impractical and strenuous.
The TARGIT (TARGeted Intraoperative radioTherapy or IORT) procedure precisely delivers radiation in a single dose during the lumpectomy operation over 15– 35 minutes, using a ball-shaped device that is placed in the space where the tumour was. This way, unnecessary potentially harmful radiation to healthy tissues (skin, heart, lungs, etc.) is avoided and the areas nearest to the tumour site receive the most radiation. In this way, four-fifths of patients avoid EBRT altogether.
The TARGIT-A (TARGeted Intraoperative radioTherapy Alone) trial compared Intrabeam TARGIT IORT with EBRT in 3451 patients who were aged≥ 45 years and found that, when TARGIT is given with lumpectomy, the control of breast cancer is much the same as with EBRT. The chances of being alive without return of cancer in the breast at 5 years were 93.9% with TARGIT during lumpectomy and 92.5% with EBRT. Compared with EBRT, TARGIT had fewer side effects and fewer deaths from heart attacks or other cancers. TARGIT IORT would be less expensive than EBRT, potentially saving the NHS up to £9.1 million a year, without considering the cost savings to patients.
Targeted intraoperative radiotherapy IORT during lumpectomy is an effective, safer and less expensive option for eligible patients.